Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine

This study demonstrates that while human adenovirus serotype 4 (Ad4) exhibits limited replication in BALB/c mice, it still supports sufficient transgene expression to elicit protective immune responses against herpes simplex virus type 2, validating the mouse model for evaluating Ad4-based vaccine candidates.

The Gist

Imagine you have a tiny, friendly delivery truck called Adenovirus 4 (Ad4). For years, the military has used this truck to drop off "safety packages" into people's mouths to protect them from getting sick in their lungs. It works great in humans, hamsters, and monkeys. But scientists really wanted to test new versions of these trucks using mice, because mice are like a super-powered laboratory where you have a huge toolkit to study how the immune system works.

The problem? Scientists were worried the Ad4 truck couldn't drive at all in mice. They thought the mice were like a locked garage where the truck just sat idle and did nothing.

The Experiment: Sending in the Scouts
To see if the truck could actually move in mice, the researchers built two special versions of the Ad4 truck:

1. The Light-Up Truck (Ad4-Luc): This truck carries a glowing lantern (luciferase). If the truck is working, it shines a light that scientists can see.
2. The Shield Truck (Ad4-gD2): This truck carries a piece of a different enemy, the Herpes Simplex Virus (HSV-2), specifically a "shield" piece called glycoprotein D. The goal was to see if this would teach the mouse's immune system how to fight HSV-2.

What They Found

• The Light Shines: When they dropped the Light-Up Truck into the noses of mice, the lantern started glowing within 7 hours and kept shining for 20 days. This proved the truck could get in and do its job.
• The "Second Visit" Problem: When they sent the truck in a second time, the light got dimmer in normal mice. It was as if the mice's immune system recognized the truck and put up a "Do Not Enter" sign, slowing it down. However, in "humanized" mice (mice engineered to act more like humans), the light stayed bright, suggesting the immune reaction was different.
• The Hidden Engine: Here is the tricky part. The researchers gave some mice a medicine (cidofovir) that stops viruses from copying themselves. Even with the medicine, they found the truck's DNA (the blueprints) in the lungs, but the light was off. This is like finding a car engine that is still turning over, even if the headlights are broken. It suggests the truck was actually driving and replicating in the mice, but just very quietly and slowly. The mice aren't a perfect garage; they are more like a "semi-permissive" parking lot where the truck can move, but not as freely as in humans.

The Big Win: The Shield Works
Finally, they tested the Shield Truck. They vaccinated mice with the Ad4 truck carrying the HSV-2 shield piece.

• The Result: The mice's blood developed special "keys" (antibodies) that could unlock and neutralize the real HSV-2 virus.
• The Challenge: When the researchers later exposed these vaccinated mice to the actual HSV-2 virus (by putting it in their vaginas), the vaccinated mice did much better than the unvaccinated ones. They got sicker less often, survived more often, and shed less of the virus into the world.

The Bottom Line
This paper tells us that mice aren't a perfect match for human Ad4 vaccines because the virus replicates very quietly there, but it's enough to work. The mice can still "see" the vaccine, build a defense, and get protected against future attacks. This means scientists can finally use these handy mouse models to test new Ad4-based vaccines without worrying that the virus is completely invisible in the system.

Technical Summary

Technical Summary: Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model

Problem Statement
Human adenovirus serotype 4 (Ad4) is established as a safe, replication-competent oral vaccine for preventing respiratory illness in US military personnel. Recombinant Ad4 vectors have demonstrated the ability to elicit robust mucosal and systemic immune responses against respiratory viruses in hamsters, nonhuman primates, and humans. Despite the extensive availability of immunologic tools in mice, which would make them an ideal model for evaluating Ad4 vaccine candidates, their utility has been historically limited. This limitation stems from concerns regarding the lack of viral replication in murine models, raising questions about whether Ad4-based vectors can effectively function or be studied in this species.

Methodology
To address these limitations, the study generated recombinant Ad4 vectors expressing either luciferase (Ad4-Luc) or herpes simplex virus type 2 (HSV-2) glycoprotein D (Ad4-gD2). These vectors were utilized to investigate three primary objectives:

1. Transgene Expression Kinetics: Monitoring the temporal profile of gene expression following intranasal inoculation.
2. Vector Replication: Assessing the presence and extent of Ad4 replication in the lungs.
3. Vaccine Efficacy: Evaluating HSV-2 immune responses and protection against challenge.

The experiments were conducted in BALB/c mice and humanized mice. To specifically test for replication, a subset of BALB/c mice was treated with cidofovir (an antiviral agent) prior to Ad4-Luc inoculation. Luciferase activity was measured from 7 hours to 20 days post-inoculation. For the vaccine efficacy component, mice were vaccinated intranasally with Ad4-gD2 and subsequently subjected to an intravaginal HSV-2 challenge. Outcomes measured included serum neutralizing antibody titers, disease scores, survival rates, and viral shedding.

Key Results

• Expression Kinetics: Local luciferase activity was detected in both BALB/c and humanized mice from 7 hours up to 20 days post-inoculation.
• Immune Response to Vector: Upon subsequent inoculation with Ad4-Luc, BALB/c mice exhibited reduced luciferase expression, whereas humanized mice maintained robust expression. This suggests that wild-type mice mount an immune response against the vector that limits secondary transgene expression.
• Replication Evidence: In BALB/c mice treated with cidofovir, Ad4 DNA levels in the lungs were reduced compared to untreated controls, while luciferase activity remained detectable. This dissociation implies that Ad4 does replicate in the lungs of BALB/c mice, albeit at a low level, and that this replication contributes to the observed antigen load.
• Vaccine Protection: Intranasal vaccination with Ad4-gD2 successfully induced HSV-2 neutralizing antibodies in the serum. Following intravaginal HSV-2 challenge, vaccinated mice demonstrated reduced disease scores, increased survival, and reduced viral shedding compared to controls.

Significance and Claims
The paper concludes that the BALB/c mouse model is "semi-permissive" to Ad4 mucosal infection. While the virus replicates at low levels and is subject to immune clearance upon re-challenge, the level of transgene expression achieved is sufficient for the study of Ad4-based vaccine candidates. The study validates the use of this murine model for evaluating the immunogenicity and protective efficacy of recombinant Ad4 vectors, specifically demonstrating their potential as a vaccine platform against HSV-2.